PGV-001
- Generic Name
- PGV-001
The Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in the Adjuvant Setting.
Phase 1
Active, not recruiting
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2021-08-18
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Ashutosh Kumar Tewari
- Target Recruit Count
- 27
- Registration Number
- NCT05010200
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai (ISMMS), New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath